Jiazhu Hu

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Pharmacovigilance analysis of immune checkpoint inhibitor-associated optic nerve toxicity based on the FAERS database.

Pharmacovigilance analysis of immune checkpoint inhibitor-associated optic nerve toxicity based on the FAERS database.

Journal: Frontiers in pharmacology
Published: April 02, 2026

Case Report: A successful rechallenge with aumolertinib after osimertinib-induced severe interstitial lung disease.

Case Report: A successful rechallenge with aumolertinib after osimertinib-induced severe interstitial lung disease.

Journal: Frontiers in pharmacology
Published: January 12, 2026

Case Report: Subacute cutaneous lupus erythematosus induced by the anti-PD-1 antibody camrelizumab combined with chemotherapy.

Case Report: Subacute cutaneous lupus erythematosus induced by the anti-PD-1 antibody camrelizumab combined with chemotherapy.

Journal: Frontiers in immunology
Published: December 04, 2024

Erratum: Adipocytes fuel gastric cancer omental metastasis via PITPNC1-mediated fatty acid metabolic reprogramming: Erratum.

Erratum: Adipocytes fuel gastric cancer omental metastasis via PITPNC1-mediated fatty acid metabolic reprogramming: Erratum.

Journal: Theranostics
Published: September 23, 2024

Development and validation of a nomogram for differentiating immune checkpoint inhibitor-related pneumonitis from pneumonia in patients undergoing immunochemotherapy: a multicenter, real-world, retrospective study.

Development and validation of a nomogram for differentiating immune checkpoint inhibitor-related pneumonitis from pneumonia in patients undergoing immunochemotherapy: a multicenter, real-world, retrospective study.

Journal: Frontiers in immunology
Published: September 12, 2024

Immune checkpoint inhibitors' combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis.

Immune checkpoint inhibitors' combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis.

Journal: Journal of cancer research and clinical oncology
Published: May 09, 2022

Down-regulated NEDD4L facilitates tumor progression through activating Notch signaling in lung adenocarcinoma.

Down-regulated NEDD4L facilitates tumor progression through activating Notch signaling in lung adenocarcinoma.

Journal: PeerJ
Published: December 21, 2021

Adipocytes fuel gastric cancer omental metastasis via PITPNC1-mediated fatty acid metabolic reprogramming.

Adipocytes fuel gastric cancer omental metastasis via PITPNC1-mediated fatty acid metabolic reprogramming.

Journal: Theranostics
Published: June 30, 2018

Current Smoking has a Detrimental Effect on Survival for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) negative Advanced non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Treated with Pemetrexed Continuation Maintenance.

Current Smoking has a Detrimental Effect on Survival for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) negative Advanced non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Treated with Pemetrexed Continuation Maintenance.

Journal: Journal of Cancer
Published: January 10, 2018

Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib.

Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib.

Journal: The Journal of international medical research
Published: January 10, 2018

Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI.

Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI.

Journal: Journal of Cancer
Published: August 15, 2017

Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors.

Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors.

Journal: Oncotarget
Published: April 16, 2017
Showing 1-12 of 14

Last Updated: 09/26/2026